LONDON (Reuters) - U.S. biotechnology group Amgen Inc has agreed to buy unlisted Decode Genetics, a pioneer in hunting down genes linked to disease, for $415 million in cash to boost its drive to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback